Importantly, the finding that these genes are suppressed by testosterone, and induced by both enzalutamide and estradiol suggests that prostate cancer interaction with the osteogenic niche in therapeutic conditions produces a microenvironment for hormone independent activation of Src. This evidence concerns the gene SRC and Familial prostate cancer.